Multi-Investigator Cooperative Comparative Studies in Clinical Research  by Vogt, Frank C. & Rostenberg, Adolph
TuE JouHNAI~ OF I Nvt::STICIATtv.: D.:nMATOtom· 
Copy righL © 1972 h.v The \Vi ll i:uns & \ Vi lkins Co. 
Vol. 58, No. 3 
Print ed i11 U.S.A. 
MULTI-INVESTIGATOR COOPERATIVE COMPARATIVE STUDIES IN CLINICAL 
RESEARCH* 
FRANK C. YOGT, M.D. AND AD OLPH ROSTEN BERG, J R., M.D.t 
ABSTRACT 
The adva ntages and the key factors in the orga ni zation and conduct of mul t i-investigator 
clinica l resea rch studi es a re discussed in PART I. In PART II t he deta il s of such a study, 
in whi ch 11 dermato logists compared two compounds a nd two vehicles s imul ta neously for 
relative effectiveness a nd sa fety, a re desc ri bed. 
Co mpa rative t ria ls to dete rmine t he relative 
effectiven ess a nd safety of prepa rations are essen-
tial to ac hieve opt ima l t reatment . To determine 
t h e prefe rred pre pa rat io n for to pi ca l th era py, 
such t ria ls may incl ude the compari so n of severa l 
concentrations of a compound, or t he co mpari son 
of o n e concen tration in differen t vehicl es, or the 
co mparison of diffe rent active compounds used 
for t h e sa me indi cation. 
T his pa per reports a cooperative, double-blind 
study by elev en in ves ti gators compa rin g three 
p r e p a rations conta ining t wo adrenocort icosteroids 
in two vehicles in the t reatment of psoriasis. In 
Pa r t I t he a d va n tages of mul t i-in vest igato r 
studies a re dis cussed, while in Part II the orga ni -
zation , conduct a nd resul ts of such a study a re 
given. 
Part I 
A properly conducted mul t i-investigato r co m-
par ative study, in our judgment, has ma ny advan -
tages: 1) s ince each investigato r need study only a 
relatively few cases, each patient can be ca refull y 
an d t horoughl y a ppraised , whil e in a reasonably 
shor t t ime sufficient cases can be obta ined ; 2) in 
addit ion to obta ining the clinica l observati ons of 
rnan y ·experi en ced physicia ns, ident ification can 
be m ade of wha tever va riat ions mi ght be intro-
d u ced by geogra phi ca l and climati c factors, or by 
the nature of patien ts seen in hos pi ta l clini cs as 
com pared to private practices; 3) the resul ts of 
the individua l studies can be both compared and 
combined to assure conclusions which a re both 
medica ll y a nd statistically va lid . 
A met iculously d esigned a nd executed study 
not only ensures tha t a conclusion of a di fference 
is va lid , bu t will a lso avo id the pi tfa ll of a ppa rent 
equ iva lency when the diffe rences are sma ll. 
While in any study compliance wit h t he pro-
tocol is necessa ry, mul t i-inves ti gato r studi es 
demand ri gid adherence to a common protocol to 
m inimize variation between investigators in order 
that the data may be pooled va lidly. E xperienced 
investigators should be se lected . It should be 
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stressed tha t the principa l investigato r must not 
delegate the study to ma ny co- investigators, who 
may inad vertent ly in t roduce deviations, pa rt icu-
larly by us ing different cri teria for grading. 
In des ign ing the protocol, a pa rt from deta il s of 
dose, frequency of observation, a nd the pa ra me-
ters to be eva luated, t he cri teria fo r grading must 
be clea rly specifi ed. T o elimina te bi as, pa ti ents 
must be ra ndomly assigned to t he preparations to 
be compared, wi t hout the investigato r kn owing 
whi ch medication is used by a ny given pa ti en t. 
A meeting attended by all invest igators p rior to 
the start of the study is essential to ensure that 
each in vestiga tor clea rly understands and also 
agrees to follow t he protocol wi thout deviat ion. 
To this end, the proposed protocol a nd case re-
port forms must be reviewed li tera lly line by line, 
discussed when ever necessary, a nd the fina l de-
ta ils agreed upon. In particula r, mut ual agree-
ment to abid e by establi shed cri te ri a for evalu -
ating change is vi ta l for uniform grading and 
valid pooling of data. 
Following completion of the study, addi t iona l 
meetings at which each investigator revi ews the 
tabulation of his data a nd the combined data of 
a ll investigators a re va luab le to as ure that all 
concur in the in terpretations and conclusions. 
Part II 
El even investiaators whose nam es a nd loca-
t ions a re given ~1 Table I, pa rt ici pated in the 
study. 
M ETH ODS 
S tudy Organization 
To achieve these ends, a protocol was drafted in 
which psoriatic pat ients, selected in accordance wi th 
spec ifi c cri te ria enumerated later, were to be treated fo r 
four wee ks, wi th rev isit evaluations wee kly. Twice daily 
application without occlusion was specified. At each 
revisit the frequency of use was confirmed and an esti-
mate was made to the _nearest quarter-tube from re-
turned tubes, of the amoun t used each week. Conco mi -
ta nt t reatment of any kind was inquired about at each 
visit and recorded. 
Test Preparations 
Two ste roids and two vehi cles were co mpared, 
namely: 
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TABLE 1 
J oseph E lliott, M.D. Norman Ka nof, M.D. 
Charlotte, North Carolina 
E rvin Epstein, M .D. 
New York, New York 
Mil ton Orkin, M.D. 
Oakland, Californ ia 
Maurice Fliegelman , M.D. 
Louisv ille, Kentucky 
Homer Harris, M .D. 
Seattle, Washington 
John Haeberlin , M.D. 
Chicago, Illinois 
Otis J illson , M .D. 
Ba ngor, Maine 
1. An ointment conta ining a topical steroid in a 
0.025% concen t rat ion, whic h is a ma rketed 
product. T he base is described as petrolatum 
without excipi ents. T he tubes used were purchased 
on the open market and were in no way alte red, 
save for being relabeled. For convenience in this 
report, the Jetter At is used to desi gnate this prep-
aration. 
2. An investigative topical steroid in a 0.1% concen-
trat ion, which was furnished in two vehicles: 
(a) White petrolatum, U.S.P. This preparation is 
designated prepa ration B:t in this report. 
(b) A base formul ated from hydrogenated lanolin , 
liqu id petrolatum , U,S.P, a nd whi te petrola-
tum, U.S.P ., designated preparation C.t 
All prepa rations resembled one a nother so closely that 
identification by sight or fee l was not possible. Each 
was suppli ed in tubes that were indistinguishable from 
one another. 
At a meetin g of all investigators a nd the authors , the 
proposed protocol and case report forms were reviewed 
a nd mutually acceptable details agreed upon. 
The criteria for patient selection specified that each 
patient must: 
1) have had psoriasis for at least 6 months prior to 
admission to this study. 
2) use no other topical or systemi c cort icosteroid 
therapy durin g the course of the study. 
3) not receive an antimetaboli te, such as Methotrex-
ate, during the study . If a pati ent has received such a 
drug within the three-month period prior to admission 
to the study, full details, including nature, dosage, dates 
of administ ration , and therapeutic resul ts, will be re-
corded. At least one month must have ela psed since the 
last dose before admission to the study. 
4) preferably not take any other medication during 
the study. If a patient is taking medicat ion for other 
reasons, such as the treatment of a ll ergic rhini tis or dia-
betes, etc. (e.g., a nt ihista mines, t ra nquilizers, a ntibiot-
ics, di gita lis , insulin), it is suggested that the med ica-
tion be continued in the sa me dose durin g the test pe-
riod, unless a change is necessary in the patient's best 
interests. Full deta ils about a ny medication used during 
the study must be recorded, including na me, dose, a nd 
frequency of admi nistration. 
5) be at least 12 yea rs old and not pregnant. 
6) agree to return for four revisits at one-week in ter-
vals. 
t Preparations B and C both conta ined betametha-
sone valerate in a 0.1 % concentration. Preparation C is 
now marketed as Va lisone Ointment 0.1 %. Prepa ra t ion 
A is Synala r (flu cina lone acetonide) Ointment 0.025%. 
Mi nneapolis, Minnesota 
E lizabeth Rauschkolb, M.D. 
Houston, Texas 
Rees .B. Rees, M.D. 
San Francisco, Ca liforn ia 
Wiley Sams, M .D. 
Miami, Florida 
It should be pointed out that paired lesion compar-
ison was NOT used . We are convinced by experience 
that, in a study using non-hospita li zed patients, paried 
les ion compa rison is inferior to the technique of random 
blind distribution of the test preparations, in which 
each patient uses only one preparation. In paired lesion 
comparisons there is the likelihood that cross-contami-
nation will occur, especially when occlusion is not used. 
Further, and most important ly, when patients a pply the 
medication at home it is not possible to be certain that 
they have not either mixed up the medications, or may 
have deliberate ly applied the one that seems to be supe-
rior to all les ions. 
The case report fo rms, designed specifically for this 
study, consisted of an inst ruction page, an initial visi t 
page, a dermogram page (a front and back sketch of the 
human figure) for indicating t reated areas, four ident ical 
return visit pages, and a fin a l summary page. 
Each invest igator was supplied with pre-numbered 
sets of case report forms, to which patients were as-
signed sequentia lly as they entered the study. These 
numbers ass igned the patient, by means of a master 
code for that study, to numbered boxes contai ning tubes 
of the preparation to be used by each patient. Thus, 
each invest igator had the test preparations randomly 
distributed a mong his patients, a nd he did not know 
nor could he cont rol which patient received which medi-
cation. 
Study Conduct 
The instruct ion page (Fig. 1) included speci fi c criteria 
for evaluat ing pruri tus and overall improvement in ad-
dition to general instructions for completing the forms . 
T he ini t ia l visit page (Fig. 2) and dermogram (Fig. 3) 
were completed at the first visit. The tota l duration of 
the patient's psorias is, its status (stable, or exacerbating 
or improving, either slowly or rapidly) , and the duration 
of exacerbation (if occurrin g) were recorded. Severi ty 
was graded for four parameters (pruritus, inf1a mmation, 
scaling, excoriation), both at th is visit and at each of the 
four weekly return visits, to permit any change to be 
specifica lly identified . While some of these parameters 
may not appear to be the best ones to evaluate pso-
riasis, we wished to use parameters that would be objec-
t ive a nd subject to se mi -quantification. Two methods of 
grading, discont inuous and cont inuous were used. The 
former uses four boxes labeled none, mild, moderate 
a nd severe, of which the most appropriate is checked ; 
the latter allows grading at any point from absent to 
greatest severi ty by marking the appropriate spot on the 
scale. One reason for this duplication was to chec k accu-
\ 
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IN V ESTIGATOR IOENTI F ICATI O N DO NOT WRITE IN THIS AREA 
I I I 
I I I 
In completing t his form, please r e f e r to the pro t o col, and pl ease: 
•Use blac k ink. 
eBe sure there is an entry for each i t em . 
eSign each page. 
•In evaluating pruritus , include the visible crite ria: 
For mild: No excoriations evident 
For severe: Excoriations ~ be evident 
ein evaluating improvement, use the c riteria: 
Exc ellent: 75% or more improve ment 
Good: 50 - 75% improvement 
Fair or poor: less than 50% improvement 
ein grading signs and symptoms, r e member t his ref e rs to the 
severity of the sign or symptom at the t ime o f that visit, 
and not to the degree of impro vement. 
•Complete both methods o f grading for pruritus, excoriations, 
inflammation, and scaling: 
a. 
b. 
The box method, using this code : 
0 None E X AMPLES 
1 Mild PRURITU S Do ~I D2 D3 MILD 2 = Moderate PRURITU S 
3 Severe 
INFLAMMATI ON 
Do D ' D 2 ~3 SEVERE INFLAMMATION 
Continuous scale method: 
The continuo us s c ales, as e x e mplified belo w, allow 
evaluation ( grading ) of t he pati ent"s disease a t 
any of a number of points from absen t to g reatest 
severity , by marking "X" at the appro priate 
point on the s c ale. 
~L~-.---.----r---r-S~C-ATL~IN~G~---,----r---r-~1 GRE AT EST 
AB SE NT r SEVE RIT Y 
~---,---,--~r---rE~X£f=OTR~IA~T~ITO~N~S-.----r---r-~~ GRE ATEST ABSENT I " I I SEVERIT Y 




racy; another was to determine whi ch method was pre-
ferred by the investiga tors ; and a third was to ascerta in 
which was better sui ted for computer a na lys is. 
A t each of the four weekly revisits the pat ient was 
gra d ed for the pa ra meters stated a bove using an iden-
tical report form (Fig. 4) fill ed out by the phys icia n. 
T h ese evaluat ions were based on t he a ppea ra nce of the 
psoriasis at that visit without consul t ing the previous 
evalua t ion. At each rev isit the frequency of applicat ion 
and any concomi tant treatment used during the pre-
ceding week was recorded. In addi t ion, side effects or 
their absence were recorded, plus any comments by ei-
ther the pa tient or the phys ician. On the final su mmary 
page (Fig. 5), in addi t ion to eva luating the overa ll thera-
peutic resul ts, a co mparison was made with prior t reat-
ment, which could be ident ified. 
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SCHERING CORPORATION 
CASE REPORT 
VALISONE OINTMENT 0. 1% 
v s . 
'E S' !GATOR ID ENT IFIC A TION 
SYNALAR OINTMENT 0.025% 
IN TREATING PSORIASIS 
PATIENT TRE A TMENT NO, 
INITIAL VISIT 
PATIENT ' S NAME 
PRIMARY 01 AG N OS\5 
EXACERBA TIN G 
lnMAL.E In FEM AL 
DATE. T REATMEN T STARTED 
MO DAY YR 
AGE ' WEIGHT ! RACE 
lncAUCAS IAN nN EGRO nMONGOLIAN 
1TOTA L DURAT I ON ! DURAT I ON OF PRESENT EXACERBAT I ON 
DI SEASE STATUS 
EXACERBATING 0 RAPIDLY O sLOW LY O sTAB LE IM PROV IN G O s LoWLY IMPROVING 0 RAPIDLY 
OTHER 0 1 AGNOSES 
PREVIOUS MED I CAT I O N 
QNONE 
CONCOMITANT TH ERAPY 
0 NONE 
SEVER I TY OF SI GNS & SYMPTOMS IN AR EAS TO BE T REATED• 
PRIJRITU S 
Do 0 1 02 03 
EXCORIAT I ONS 
Do D• D2 D3 
I NF L AMMAT I ON 
Do D• D2 D3 
INDI C ATE THE SEVERIT Y OF THE SIGNS AND SY MPTOMS PRESENT ON THE SCALES BE L OW BY MARKING AN 
" X " AT THE APPROPRIATE POINT• 
~------~----~r-----~------~E_x_c_o __ R,IA_T __ IO_N_s _ ,_-----,-------,------.------41 GREATEST ABSENT SEVER ITY 
r------~------.-----~------,-IN __ F_L_A_M,M_A_T __ ID_N __ r------,-------,------,------11 GREA T EST ABSENT SEVERITY 
COMMENTS---------------------------------------------------------------------------------
SIGNED ----------------------------~DAT E ____________ __ 
•SEE INST R U C TI ON PAGE Q t e·t t / e7 
FIG. 2. Initia l visit page 
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SCHER ING CORPORATION 
CASE REPORT 
VALISONE OINTMENT 0.1% 
vs . 
SYNALAR OINTMENT 0.025% 
IN TREATING PSORIASIS 
SHADE AREAS TREATED 
NVEST IC ATOR IDENTIFICATION 
PATIENT'S NAME 
PAT I ENT TREATMENT N O . 
FIG. 3. Dermogram page 
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SCHER ING CORPORATION 
CASE REPORT 
VALISONE OINTMENT 0. 1% 
vs. 
SYNALAR OINTMENT 0.02S% 
IN TREATING PSORIASIS 
FOLLOW-UP VISIT 
0 1st 0 2nd 0 3rd 0 4th 
e COMPLETE THIS PAGE WITH O UT REFER-
ENCE TO PRECEEDING EVALUATIONS 
I NV ESTI GATOR I DENT I FICATION 
MO DAY 
PAT IENT TREATMENT NO. I TODAY'S DATE 
PATIENT NAME 
VR 
PAT I E NT APPL I ED MEDICATION S tCHECK O N E BOX ONLY) 
D I X DA Y D BID D TID D OlD D MORE THAN OlD I NO . OF WHOL E A N D FRACTIONAL TU BES USED S INCE LAST VIS I T. RECORD FRACTION TO NEAREST 1/ 4 
EVA LU ATION OF T H ERAPEUT I C RESUL T (CHECK ONE BOX ONLY) • 
D CLEARED D E XCE LLENT DGOOD D FAIR OR POO R D NO EFFECT D E XA CERBATION 
SEVERITY OF S IGNS AND SYMPTOMS IN TREATED AREA S • 
PRURITUS INFLAMMATION 
EXCORIATIONS SCA LIN G 
Do D 1 Dz D3 Do D 1 Dz 03 
INDICATE THE SEVERITY OF THE SI GNS AND SYMPTOMS PRESENT ON THE SC ALE S BELOW BY MARKING AN 
" X " AT THE APPROPRIATE POINT• 
I PRURITUS I GREATEST ABSENT~------~----~r------r------~----~r-----~------,-----~-------r------4. SEVERITY 
I EXCORIATION S I ABSENT ~------r------,-------r------~----~-------r------~-----,-------r------4 GREATEST SEVERIT"'' 
I INFLAMMATION I GREATEST ABSENT ~------r------,-------r------~----~------~------,------,-------r------~. SEVER ITY 
I SC ALING I GREATEST ABS E N T r------r------,-----~r------r------,-------r------T------~-----,-------4. SEVERIT Y 
S I DE EFFECTS 
D NONE DYES (SPECIFY} 
CONCOMITANT THERAPY 
DNONE 
CO MMEN TS: 
SIGNED ----------------------DATE----------
•SEE INSTRUCTION PAGE 
e BE SURE VISIT HUMBER IS CHECKED AT TOP OF PAGE 
FIG. 4. Return visit page 
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SCHERING CORPORATI ON 
CASE REPOR T 
VALISONE OINTMENT 0. 1% 
vs . 
SYNALAR OINTMENT 0.025% 
IN TREATING PSORIASIS 
OVERALL THERAPEUTIC EVALUATION 
(AFTER LAST VISIT) 
INVESTIGATOR I DEN T IFICAT I ON 
M O D AY 
P A TIENT TRE A TMEN T NO. J TOOAV ' S DA T E 
PA TI E N T ' S N A M E 
RES U LTS OF TRE A TM EN T 
(CHECK O N E BOX O NL Y ) 
0 CLEARED 
0 EXCEL LENT 
0GDOD 
0 F A I R OR POOR 
0 NO EF F ECT 
0 E X A C ER B ATION 
0 NO EVA L UATI ON-REASON--- ------
COM P ARE D TO PREV IOU5- TR EATMENT! 
( P L EA SE SPECIFY ) 
0 BETT ER 
0 SAME 
0 WO RS E 
YR 
OVE R AL L AD VERSE E F FECTS OR TO XI C REAC T I O N S : 0 N ON E OR ------- - --------
COMM E NTS __________ _ ___ _ _ __________________ ___
___
 _ 
TR E AT MENT T E RMIN A T ED 
M O NTH DAY 
YEAR 
SI GN ED ___ ___________ ~D ATE _______ ___ __ 
g l 0- 1 1 / 6 7 
F IG. 5. Fi na l summa ry page 
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Study Manage ment 
On receipt, each report was checked for complete-
ness, and any page with a missing entry was photo-
copied and sent to the invest igator for co mpletion, if pos-
sible. Any recorded "side effects" were discussed with 
the inves ti gator to obta in his opinion of drug- related-
ness. Subsequently t he data were transc ribed to punch 
cards and eventually compute ri zed. 
Data Processing 
When the study was terminated, of a projected 440 
case reports 429 reports had been return ed, of which 39 
were incompl ete. A case report was class ified " incom-
plete" if the patient did not co mplete the four week 
course for a reason other than treatm ent fa ilure. If the 
patient or the phys ician deemed the treatment a fa ilure 
so tha t either wished to discontinue, this was done. 
Such a report was not labelled incomplete but was in-
cluded among the completed ones and listed as a t reat-
ment fa ilure for whi chever preparation had been used. 
The case reports were furth er segregated in to two 
major groups: those who had consistently used b.i.d . 
a pplication without concomi ta nt t reatment, and those 
who had either departed from b.i.d. application or had 
used conco mi tant t reatment. 
Post S tudy Discussions 
When preliminary computer print-outs beca me avail-
abl e, a second meeting wit.h the investigators was held 
and the fi ndings were discussed. A third and final 
meeting was held to review the final tabulat ions. Each 
invest igator revi ewed a computer print-out of his data, 
and also one combining the data from all investiga tors, 
plus a draft of this paper, to assure that a ll concurred in 
the conclusions. Th ese meetings with the investi gators 
were very valuable, for, in addition to revi ewing the re-
sults with them, their suggestions and support of the 
interpretat ions added to the authori ty of the conclu-
sions. 
RESULTS 
The 390 complete case re ports were ta bulated 
as a group a nd a lso aft er sepa ra ti on in to t wo 
major categori es. One group was ma d e up o f 259 
patients who throu ghout the s tudy a pplie d t he 
ointment consisten t ly t wi ce a d ay a nd used no 
concomitant t reatment. 
The fo llowing summary of results is a bstracted 
from the extens ive computerized a nalysis of this 
g roup . Us in g chi -s qua re a n a lys is with Yates' . 
correctio n, t here were no significa n t differences 
(P > 0.05) for th e para mete rs of sex, age, race, 
and disease status, a m ong the patients ass igned to 
t he three test preparations, which confirms the 
equiva len cy of the three pat ient groups studi ed. 
As shown in Tabl e II, prepa ration C was supe-
rior (P s 0.05) to pre parat ion A fo r a ll 11 compa r-
iso ns, a nd pre paration B was superior to prepa ra -
t ion A fo r 7 of these 11 comparisons (P s 0.05) . 
Whil e for the remaining 4 compa ri so ns, pre para -
tion B was superior to prepa ration A, s in ce we 
have select ed the value P < 0.05 as t he cri t ical 
value, t hese 4 differences a re d efin ed as no n-sig-
nifica n t . It is noteworthy that for t he key pa ram -
eter of t hera peut ic resul t, prepa ration C was s ig-
T ABLE II 
Significan t di fferences (P S 0.05) 
Prcpnra t ion Prepa ration 
Return "C" su pe- "B" supe-
Parameter visit rior lo rior to Prcpam tion Prepara ti on 
no. A: p A: p 
Vo luc Value 
Scalin g 1 < 0.005 > 0.10 * 
Inflammat ion 3 < 0.05 < 0.025 
lnl1ammation 4 < 0.005 < 0.025 
Pruri tus 3 < 0.05 < 0. 10 * 
Pruri tus 4 < 0.01 > 0.10* 
Therapeut ic resul ts 1 < 0.005 < 0.05 
T11erapeut ic resul ts 2 < 0.05 > 0. 10 * 
Therapeutic resul ts 3 < 0.005 < 0.01 
Therapeut ic resul ts 4 < 0.005 < 0.05 
Fina l ove ra ll t hera- - < 0.005 < 0.05 
peut ic resul ts 
Co mpared to previous - < 0.005 < 0.025 
treatment 




For statistical significance the value P :; 0.05 is se-
lected as the criti cal value, i.e., the probability of con-
cluding that drugs differ when in effect they do not, is 
equal to, or less tha n, one in twenty. For P < 0.01 , the 
error rate is one in 100, and for P < 0.005 it is one in 
200. 
* Indi cates statist ically a non-s ignifi cant difference a 
defined above. 
TABLE III 
N o significant differen ce between Preparations A, B, 
and C (P > 0.05) 
Clinica l parn mclers Hcvisit no. P vulues 
lJ1f1amma tion 1, 2 p > 0.05 
Scaling 2, 3, 4 p > 0.05 
Pruri tus 1, 2 p > 0.05 
Excoriat ions 1, 2, 3, 4 p > 0.05 
TABLE IV 
Final therapeutic results by number and % of pat1:ents 
Prcpara - PrepMH · Prepam -
tion A lion 13 Linn C T otal 
Cleared 4 3% 5 7% 9 14% 18 7% 
Excellent 18 15% 16 23% 19 28% 53 20% 
Good 38 32% 28 39% 21 31% 87 34% 
Fair or Poor 39 32% 16 23% 12 18% 67 26% 
No effect 11 9% 1 1% 4 6% 16 6% 
Exacerbation 11 9% 5 7% 2 3% 18 7% 
121 71 67 259 
nifi cantl y sup erior t o pre pa ra t ion A at a ll four 
revis its, and prepa ration B at three of t he four 
revis its . The instances in which no s ignifi ca n t di f-
ferences b etween t h e t hree preparations w er e 
MULTI-IN VESTIGATOR ST UDIES 147 
foun d are listed in Table III. T hese comparisons 
are d efined as non-s igni ficant by again using P < 
0.05 as t he cri t ica l va lue, a lt hough in many in -
sta nces prepa rations B and C were numeri ca lly 
favored . 
O f pa rt icular in te rest a re the fina l therapeut ic 
. resul t ra tings, summari zed in Table IV. T hese 
ratings we re a rrived at by the investigators fo l-
lowin g the fourth rev is it using t he cri teria s pec i-
fied for this study. P repa rations B and C a re su-
perior to prepa ration A (P ::; 0.05). 
It was thought that pa ramete rs such as di sease 
s tatu s, duration, pruri tus, infla mmation, sca ling 
and excoriation at the ini t ia l vis it might prove 
J. helpful in foretelling the ul t imate therapeut ic 
result, but t his did not prove to be the case. No 
s ign ifica n t co rrelat ion could be demonst rated 
between any of these para meters and the ul t imate 
response to t reatmen t. 
In each of the ten instances of " side effects" 
recorded , t he dec is ion as to whether or not the 
" side effect" was drug related was made by t he 
reporting investigato r. T he "side effects" were : 
candid ias is 1, contact dermatit is 1, folli culi t is 3, 
furuncle 1, irritation 1, in creased itching 1, ques-
t ionab le photosensit iv ity 1, bulla 1. All instances 
were t rivial, and the last two, in our opinion, were 
probably not drug related . There was no signifi-
ca nt difference (P > 0.05) between the three 
prepa rations in incidence of " sid e effects" . 
CON CLUS IONS 
T his study demonstrates the usefulness of a 
mul t i-in vestigator study to com pare two com-
pounds and two vehi cles simul tan eously for rela-
t ive effectiveness and safety. 
The a uthors and the 11 investigators conclude 
t hat pre parations B and C are superior to prepa-
rat ion A when a pplied twice da ily wi thout occlu -
sion for four weeks in the t reatment of psoriasis. 
